|
|
Other links at Articles > Cardiology |
| 2. |
AHA 2008: New Factor Xa Inhibitor Rivaroxaban Moves Into Phase 3 for ACS
|
|
|
A phase 2 trial has demonstrated the feasibility of the novel oral factor Xa inhibitor rivaroxaban in patients with acute coronary syndromes already treated with aspirin and clopidogrel. A phase 3 study with the drug, beginning next month, will reveal whether the benefits outweigh the bleeding risks. Heartwire
|
|
|